NOV:ETR
Novo Nordisk A/S
34,45 €
arrow_upward
+0,53%(+0,18) 1D
12 okt, 17:35:58 GMT+2 · EUR
search
Bütün simvollar
| Simvol | Qiymət | Dəyişiklik | % Dəyişiklik |
|---|
insights_autoNOV üçün ən vacib statistik məlumatlar yaradılır...
Açın
34,40 €
Yüksək
34,75 €
Aşağı
34,22 €
Bazar kapitalizasiyası
129,60 mlrd
Ortalama həcm
181,05K
Həcm
84,50K
52 həftəlik ən yüksək
54,87 €
52 həftəlik ən aşağı
30,24 €
İşçilərin sayı
67K
Açın
34,40 €
Yüksək
34,75 €
Aşağı
34,22 €
Bazar kapitalizasiyası
129,60 mlrd
Ortalama həcm
181,05K
Həcm
84,50K
52 həftəlik ən yüksək
54,87 €
52 həftəlik ən aşağı
30,24 €
İşçilərin sayı
67K
Xəbər materialları
Veb mənbələri və xəbər partnyorlarından
ad-hoc-news.de
·
3 saat öncə
Novo Nordisk's US Share Erosion Prompts Fresh Target Cuts as Pipeline Bets Face Delays
Yahoo Finance
·
7 saat öncə
Novo Down 11% in a Month: How Should Investors Approach the Stock Now?
Investing.com India
·
8 saat öncə
BMO cuts Novo Nordisk stock price target on Ozempic headwinds By Investing.com
Foreign Policy Journal
·
8 saat öncə
Novo Nordisk (NYSE: NVO) Repurchases Over 23 Million B Shares Under DKK 15 Billion Buyback Programme
Profil
Novo is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark's domestic economy, and it became the highest valued company in Europe. Wikipedia
Novo Nordisk A/S haqqında
Baş İcraçı DirektorMaziar Mike Doustdar
İşçilər66,7K
Təsis Tarixi1923
Baş OfisBagsværd, Capital Region of Denmark, Danimarka
SektorPharmaceutical industry
Veb-saytnovonordisk.com